MM LAB Software Matches Oncology Patients to Treatments
The software allows pathology labs, hospitals, genomic cores and physicians to match patients’ test results to personalized cancer treatments, including clinical trials and experimental drugs.
MolecularMatch, a personalized cancer treatment company launched its MM LAB software, which is available through an online portal. The software allows pathology labs, hospitals, genomic cores and physicians to match patients’ test results to personalized cancer treatments, including clinical trials and experimental drugs, in real-time. After test results are matched to treatments in MM LAB, the options are curated by the client laboratory's staff and included in the reports sent back to physicians and patients. The solution works using molecular science / artificial intelligence based algorithms.
Read the full release.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
